Because this was just 2 dosing studies. It is just to determine what dose to use for future trials. Absolutely meaningless, except for the fact that at the doses they are using, the drug appears safe. Even then, "safe" is subjective and as we all learned many years ago, what Ray Warrell considers safe does not necessarily coincide with independent reviewers. All in all, ASCO was just another needless travel expense for this company. Now you have dilution and a reverse split to look forward to and many, many years of continuing clinical trials before Genta can even consider hiring a sales team. Maybe a run up next January in anticipation of a miracle on Genasense.
Good luck but I would get out now and then get back in closer to what the convertible note holders are paying - i.e. 1 penny.